Cabaletta Bio, Inc.

NasdaqGS:CABA Stok Raporu

Piyasa değeri: US$91.4m

Cabaletta Bio Yönetim

Yönetim kriter kontrolleri 2/4

Cabaletta Bio CEO'su Steven Nichtberger, Jan2017 tarihinde atandı, in görev süresi 7.83 yıldır. in toplam yıllık tazminatı $ 4.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.4% maaş ve 87.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.76% ine doğrudan sahiptir ve bu hisseler $ 2.52M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.8 yıldır.

Anahtar bilgiler

Steven Nichtberger

İcra Kurulu Başkanı

US$4.8m

Toplam tazminat

CEO maaş yüzdesi12.4%
CEO görev süresi7.8yrs
CEO sahipliği2.8%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi4.8yrs

Son yönetim güncellemeleri

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

May 22
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Dec 28
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

CEO Tazminat Analizi

Steven Nichtberger'un ücretlendirmesi Cabaletta Bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$1mUS$213k

-US$12m

Tazminat ve Piyasa: Steven 'nin toplam tazminatı ($USD 4.81M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).

Tazminat ve Kazançlar: Steven şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Steven Nichtberger (63 yo)

7.8yrs

Görev süresi

US$4,808,279

Tazminat

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
David Chang
Chief Medical Officer5.4yrsUS$2.10m0%
$ 0
Gwendolyn Binder
President of Science & Technologyno dataUS$2.34m0.041%
$ 37.4k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Anup Marda
Chief Financial Officer5.8yrsUS$1.53mVeri yok
Qing Yuan
Chief Technology Officerless than a yearVeri yokVeri yok
Samik Basu
Chief Scientific Officer3yrsVeri yokVeri yok
Michael Gerard
General Counsel & Secretary3.2yrsVeri yokVeri yok
Heather Harte-Hall
Chief Compliance Officer3yrsVeri yokVeri yok
Nicolette Sherman
Chief Human Resources Officerno dataVeri yokVeri yok
Arun Das
Chief Business Officer2.8yrsVeri yokVeri yok

3.0yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: CABA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Richard Henriques
Independent Director5.8yrsUS$259.20k0%
$ 0
Carl June
Member of Scientific Advisory Board4.3yrsVeri yokVeri yok
Mark Simon
Independent Director6.1yrsUS$260.15k0.29%
$ 267.7k
Brian Daniels
Member of Scientific Advisory Board3.4yrsUS$202.24kVeri yok
Scott Brun
Independent Director3.4yrsUS$255.83k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board4.8yrsVeri yokVeri yok
Jay Siegel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Drew Weissman
Member of Scientific Advisory Board2.9yrsVeri yokVeri yok
Catherine Bollard
Independent Director5.6yrsUS$255.43k0.0021%
$ 1.9k

4.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CABA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).